Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India.
Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri, Pune, India.
Rev Med Virol. 2022 Nov;32(6):e2390. doi: 10.1002/rmv.2390. Epub 2022 Aug 27.
With COVID-19 still hovering around and threatening the lives of many at-risk patients, an effective, quick, and inexpensive prognostic method is required. Few studies have shown fibrinogen to albumin ratio (FAR) and C-reactive protein to albumin ratio (CAR) to be promising as prognostic markers for COVID-19 disease. However, their implications remain unclear. This meta-analysis aimed to elucidate the prognostic role of FAR and CAR in COVID-19 disease. A systematic literature search was undertaken using PubMed and Embase till April 2022. Inverse variance standardised mean difference (SMD) was calculated to report the overall effect size using random effect models. The generic inverse variance random-effects method was used to pool the area under the curve (AUC) values. All statistical analyses were performed on Revman and MedCalc Software. A total of 23 studies were included. COVID-19 non-survivors had a higher CAR on admission compared with survivors (SMD = 1.79 [1.04, 2.55]; p < 0.00001; I = 97%) and patients with a severe COVID-19 infection had a higher CAR on admission than non-severe patients (SMD = 1.21 [0.54, 1.89]; p = 0.0004; I = 97%). Similarly, higher mean FAR values on admission were significantly associated with COVID-19 mortality (SMD = 0.55 [0.32, 0.78]; p < 0.00001; I = 82%). However, no significant association was found between mean FAR on admission and COVID-19 severity (SMD = 0.54 [-0.09, 1.18]; p = 0.09; I = 91%). The pooled AUC values found that CAR had a good discriminatory-power to predict COVID-19 severity (AUC = 0.81 [0.75, 0.86]; p < 0.00001; I = 80%) and mortality (AUC = 0.81 [0.74, 0.87]; p < 0.00001; I = 86%). FAR had a fair discriminatory-power to predict COVID-19 severity (AUC = 0.73 [0.64, 0.82]; p < 0.00001; I = 89%). Overall, CAR was a good predictor of both severity and mortality associated with COVID-19 infection. Similarly, FAR was a satisfactory predictor of COVID-19 mortality but not severity.
由于 COVID-19 仍然存在并威胁着许多高危患者的生命,因此需要一种有效、快速且廉价的预后方法。一些研究表明,纤维蛋白原与白蛋白比值(FAR)和 C 反应蛋白与白蛋白比值(CAR)是 COVID-19 疾病有前途的预后标志物。然而,其意义仍不清楚。本荟萃分析旨在阐明 FAR 和 CAR 在 COVID-19 疾病中的预后作用。使用 PubMed 和 Embase 进行了系统的文献检索,检索时间截至 2022 年 4 月。使用随机效应模型计算逆方差标准化均数差(SMD)以报告总体效应大小。使用通用逆方差随机效应方法汇总曲线下面积(AUC)值。所有统计分析均在 Revman 和 MedCalc 软件上进行。共纳入 23 项研究。COVID-19 非幸存者入院时的 CAR 高于幸存者(SMD=1.79 [1.04, 2.55];p<0.00001;I=97%),严重 COVID-19 感染患者的 CAR 高于非严重患者(SMD=1.21 [0.54, 1.89];p=0.0004;I=97%)。同样,入院时较高的平均 FAR 值与 COVID-19 死亡率显著相关(SMD=0.55 [0.32, 0.78];p<0.00001;I=82%)。然而,入院时 FAR 值与 COVID-19 严重程度之间没有发现显著相关性(SMD=0.54 [-0.09, 1.18];p=0.09;I=91%)。汇总的 AUC 值表明,CAR 具有良好的预测 COVID-19 严重程度的区分能力(AUC=0.81 [0.75, 0.86];p<0.00001;I=80%)和死亡率(AUC=0.81 [0.74, 0.87];p<0.00001;I=86%)。FAR 对预测 COVID-19 严重程度具有适度的区分能力(AUC=0.73 [0.64, 0.82];p<0.00001;I=89%)。总体而言,CAR 是 COVID-19 感染严重程度和死亡率的良好预测指标。同样,FAR 是 COVID-19 死亡率的满意预测指标,但不是严重程度的预测指标。